60 results about "Polysorbate 80" patented technology

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.

Provided are pharmaceutical formulations comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.

The application relates to the technical field of cough-relieving medicines, and discloses a high-efficiency cough-relieving loquat particle composition which is composed of the following components in parts by weight: loquat leaf extract 30-40 parts; white front extract 10-15 parts; platycodon grandiflorum extract 6-10 parts; white mulberry bark extract 18-25 parts; stemona sessiliflora extract 7-10 parts; menthol 0.1-0.5 part; polyethylene glycol 2-5 parts; mannitol 8-12 parts; ethyl cellulose 3-6 parts; hydroxypropyl methyl cellulose 1-3 parts; phosphatidylcholine 1-3 parts; polysorbate 80 1-3 parts; cross-linked sodium carboxymethyl cellulose 4-6 parts; and sucrose 40-60 parts. The double dispersion system combining the immediate-release component and the sustained-release component is adopted, the solubility and the initial release speed of the traditional Chinese medicine extract are remarkably improved through the addition of polyethylene glycol and mannitol, and the technical effect that the drug effect appearing time is remarkably shortened is achieved. Compared with the technical scheme relying on only a single release mode in the prior art, the deficiency that the drug effect is slow and the symptoms of the patient cannot be timely relieved is solved.

The application discloses a kind of bumetanide tablets, raw materials include bumetanide 1 according to mass ratio;Corn starch 81~85;Lactose 50~54;Agar 0.1~0.3;Povidone K304~6;Polysorbate 80, 0.1~0.2;Silicon dioxide 3~4.5;Talcum powder 2~3.3;Magnesium stearate 0.3~0.7.Its preparation method includes the following steps: pretreatment, premixing, granulation, wet granulation, drying, dry granulation, total mixing, tabletting and packaging.The application introduces the synergistic system of trace agar and polysorbate 80 in the prescription.Agar, as a natural hydrophilic colloid, can form a hydrophilic network structure during the granulation process, and synergistically act with polysorbate 80, greatly improving the wettability and dispersibility of the slurry to ultrafine bumetanide, preventing drug agglomeration, so that the drug can be more evenly distributed in the granules during the subsequent drying and tabletting process.

The invention discloses an oyster enzymolysis ultrafiltration extract nasal spray and a preparation method thereof, the nasal spray comprises the following components: 5-10 wt% of oyster extract, 0.1-0.3 wt% of preservative, 0.05-0.15 wt% of sodium chloride and 0.1-0.3 wt% of emulsifier, the pH value is 5.5-6.5, the content of the preservative is 0.1-0.3 wt%, the content of the sodium chloride is 0.05-0.15 wt%, the content of the emulsifier is 0.1-0.3 wt%, and the balance is water. The preservative is one of benzalkonium chloride, sorbic acid and potassium sorbate, and the emulsifier is polysorbate 80. Through definite raw material composition, a step-by-step process and quality control, the bioavailability of active components is improved, the flavor of the product is optimized, the effect of safely and efficiently improving sleep is achieved, the problems of low bioavailability, poor flavor and potential safety hazards of an existing sleep improving product are solved, the process repeatability is high, and the preparation method is suitable for industrial production. The long-term use of people with chronic insomnia is facilitated.

The invention relates to a pharmaceutical composition, which is prepared from adapalene, benzoyl peroxide, a traditional Chinese medicine extract, an acrylamide and acryloyl dimethyl sodium taurate copolymer, a mixture of isohexadecane and polysorbate 80, docusate sodium, EDTA (Ethylene Diamine Tetraacetic Acid) disodium, glycerol, poloxamer 124, propylene glycol and water, the traditional Chinese medicine extract comprises moutan bark, salvia miltiorrhiza, radix rehmanniae recen, radix sophorae flavescentis, coptis chinensis, rheum officinale, scutellaria baicalensis, menthol and borneol. According to the pharmaceutical composition disclosed by the invention, the synergistic antibacterial and anti-keratosis curative effects of adapalene and benzoyl peroxide can be maintained, and meanwhile, the occurrence rate of local skin dryness, erythema, desquamation, burning heat sensation and contact dermatitis can be remarkably reduced.

The invention discloses a method for detecting polysorbate 80 based on an MALDI-MS and UHPLC-Q-TOF / MS. The method comprises the following steps: taking a polysorbate 80 sample, preparing a polysorbate 80 solution by using acetonitrile, respectively carrying out MALDI-MS detection and UHPLC-Q-TOF / MS detection on the polysorbate 80 solution, and determining the content of the polysorbate 80 in the polysorbate 80 sample according to the MALDI-MS and UHPLC-Q-TOF / MS detection results. The method comprises the following steps: acquiring PS80 principal component distribution according to an MALDI-MS (Matrix-Assisted Laser Desorption Ionization-Mass Spectrometry) map: a polyoxyethylene chain delta m / z 44.0 + / -0.2 and an esterified derivative sodium adduct ion gradient peak cluster, and carrying out qualitative analysis on components of the polysorbate 80 in combination with a characteristic interval of m / z 44.0 + / -0.2 in the MALDI map; according to the retention time in the UHPLC-Q-TOF / MS detection result, identifying the monoester, diester and trace unesterified sorbitan in the polysorbate 80. According to the invention, molecular weight distribution analysis and component separation and identification of PS80 are realized.

A noninvasive ophthalmic formulation, comprising a chelator (such as EDTA and its salts), a transport enhancer (such as Methyl Sulfonyl Methane; MSM), a second polyoxyalkylene permeation enhancer such as propylene glycol capable of enhancing permeation through lipid-thickened ocular membranes, a thickening agent such as hydroxyethyl cellulose (HEC) and a surfactant such as polysorbate 80, is provided. The novel combination of the ingredients unexpectedly and beneficially reduces symptoms associated with early-stage, age-related cataracts. Methods for treating cataracts with compositions of the invention and measurement of improved visual function by measuring contrast sensitivity (CS) are provided.

The invention belongs to the technical field of traditional Chinese medicine navel patches, and particularly relates to a composite medicine carrying navel therapy patch based on a PU film and a preparation method thereof.The composite medicine carrying navel therapy patch comprises an anti-sticking release film, a medicine carrying layer, a medical pressure-sensitive adhesive layer and a PU waterproof protective layer; the traditional Chinese medicine extract is prepared from the following raw materials in parts by weight: 10 to 20 parts of rhizoma zingiberis, 10 to 15 parts of roasted rhizoma atractylodis macrocephalae, 8 to 12 parts of radix codonopsis, 5 to 10 parts of fructus evodiae, 5 to 10 parts of fructus foeniculi, 3 to 8 parts of cortex cinnamomi, 1 to 3 parts of borneol, 8 to 20 parts of polysorbate 80, 0.5 to 2 parts of carbomer 940, 1 to 3 parts of triethanolamine and 0.1 to 0.5 part of EDTA-2Na. By means of the integrated design of slow-release hydrogel drug loading and the multi-layer patch, efficient transdermal absorption and stable release of drugs are achieved, and the bioavailability and application comfort of the composite drug-loading navel therapy patch are improved.

The invention provides a coenzyme Q10 lipid nanocrystal which is prepared from the following raw materials in percentage by mass through a hot melt extrusion method: 10%-58% of coenzyme Q10, 9.09%-30% of glyceryl monostearate, 14.28%-20% of polysorbate 80 and 14.28%-45% of a water-soluble carrier, and the total amount of all the raw materials is 100%. The particle size of the coenzyme Q10 lipid nanocrystal ranges from 537.2 nm to 936.5 nm; the solid lipid and the water-soluble carrier are combined to serve as a dispersing agent of the coenzyme Q10, so that the coenzyme Q10 can be dispersed in the combined material in a nanocrystal form, the lipid nanocrystal with high drug loading capacity is obtained, the prepared coenzyme Q10 nanocrystal can be quickly dispersed and dissolved out in water, and the preparation method is simple in preparation condition, short in time, low in cost and suitable for industrial production. The method is suitable for industrial production.

The present invention provides compositions and methods for reducing protein loss during drug delivery caused by protein adsorption onto one or more drug delivery system components. [Solution] In some embodiments, the present disclosure provides a composition for preventing the adsorption of proteins to one or more drug delivery system components, the composition comprising succinate and polysorbate 80. In some embodiments, the composition further comprises a therapeutic protein.

The present application relates to a kind of pharmaceutical compositions for preventing and treating allergic rhinitis symptoms, with glycerin 1%~10%, polysorbate 80 0.1%~2%, sodium edetate 0.01%~1% and pharmaceutically acceptable carrier in composition by weight percentage.The composition of the present application scientifically screens components and proportion, can form long-lasting antibiofilm protective layer on nasal mucosa, regulate the rhinitis caused by nasal mucus secretion abnormality due to environment or disease and the like, and has the advantages of good biocompatibility, fast effect, good stability, long-acting water-locking, long-acting, no side effects and the like.

The invention provides a pharmaceutical formulation containing a particulate porous adsorbent selected from the group of aluminosilicates and their salts, with a neutral or basic pH and a particle size between 50 and 800 μm, onto which a mixture of polyoxyethylene sorbitan monooleate (polysorbate 80) is applied with at least one cannabinoid selected from cannabidiol, cannabigerol, cannabinol, D9-THC, and D8-THC. This formulation improves the bioavailability and release profile of the cannabinoids.

The present invention relates to insulin formulations comprising polysorbate 80. The present invention provides, inter alia, aqueous liquid pharmaceutical formulations comprising insulin or an insulin analogue, ionic zinc, a chelating agent, and polysorbate 80.

This invention provides an improved formulation and administration method of an FcRn inhibitor for use in the treatment of autoimmune diseases. [Solution] An aqueous formulation containing approximately 100-300 mg / mL of an FcRn antagonist, 20-60 mM histidine / histidine HCl, 0-70 mM sucrose, 0-150 mM NaCl, 0-250 mM arginine HCl, 0%-0.05% (w / v) polysorbate 20 or polysorbate 80, and 0-15 mM L-methionine. The aqueous formulation has a pH of 6.0-6.5, and the FcRn antagonist consists of a variant Fc region, which consists of two Fc domains that form a homodimer.

This is a recombinant human acidic fibroblast growth factor preparation, and in particular, an acidic fibroblast growth factor eye drop formulation. The eye drop formulation uses a combination of histidine, polysorbate 80, and sodium heparin as a protein protectant, eliminating the need to use human serum albumin as a protein protectant. This not only reduces costs but also effectively improves product stability, maintaining high biological activity for up to 9 months under conditions of (25±2)°C and a relative humidity of (60±5)%.

The application discloses a method for detecting the dissolution curve of ezetimibe and rosuvastatin calcium tablets, and belongs to the technical field of drug detection. The method uses an aqueous solution containing 0.1-0.3 wt% polysorbate 80 as a dissolution medium, and performs dissolution according to a dissolution instrument basket method, wherein the rotating speed of the rotating basket is 50-100 revolutions per minute, and the mesh number of the rotating basket is 10 meshes. The method provided by the application has good dissolution for both ezetimibe and rosuvastatin calcium, and has the characteristics of strong specificity, high sensitivity, high accuracy, good durability and the like, can effectively distinguish the difference between self-prepared preparations and reference preparations, and is more universal and practical, and is more simple and efficient in operation.

A composition and method for treating COVID-19 includes a first component including approximately 10 mg of dexamethasone and a second component including approximately 48 mg to 80 mg of triamcinolone acetonide in combination with sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80. When combined, the formulation provides dual-steroid therapy that reduces the need for tapering associated with high-dose dexamethasone, thereby minimizing adverse effects such as immunosuppression and secondary pneumonia. The composition is administered via injection and is effective for alleviating symptoms in patients with mild, moderate, or severe COVID-19 infections.

A pharmaceutical aerosol formulation containing pre-micronized epinephrine, a co-solvent ethanol, a surfactant polysorbate 80, and a propellant trans-1, 3, 3, 3-tetrafluoropropene (HFO-1234ze (E)) for use in a pressurized metered dose inhaler is described. The formulations provide efficient delivery of pre-micronized epinephrine particles into the respiratory tract of a patient, and have the advantages of high therapeutic efficacy, improved safety, and low global warming potential (GWP) affecting the environment.

In order to solve the problem that traditional filter material is difficult to degrade, the application discloses a kind of porous biodegradable gel filter material and its preparation method and application, the gel filter material includes chitosan, polyethylene glycol 4000 and polysorbate 80, and the mass ratio is 10-30:1-10:1-10.The gel filter material prepared by the application has good ventilation, adsorption performance, biodegradability and biocompatibility, realizes the double functions of "filtration+degradation", and can be used as a new green material for cigarette filter, and has potential application value in the production and manufacturing process of new type cigarettes.

The present disclosure relates to methods of treating cancer, such as lung cancer (e.g., non-small cell lung cancer) by administering a dry powder to the respiratory tract of a subject in need thereof (e.g., by oral inhalation), the dry powder comprising respirable dry particles that comprise an angiogenesis inhibitor (e.g., itraconazole), and optionally a stabilizer (e.g., polysorbate 80) and / or one or more excipients (e.g., leucine and a sodium salt, such as sodium sulfate).

The invention discloses a non-steroidal anti-inflammatory drug suspension drop and a preparation method thereof. The suspension drop comprises ibuprofen, xanthan gum, pregelatinized starch, glycerin, sucrose, anhydrous citric acid, sodium benzoate, polysorbate 80, strawberry essence and water. The preparation method comprises the following steps: 1) sieving ibuprofen with a 20-mesh sieve for later use; the preparation method comprises the following steps: adding polysorbate 80 into purified water, stirring and dissolving, adding ibuprofen according to the prescription amount, and stirring and dispersing uniformly; 2) adding 100 DEG C purified water and glycerol into the liquid preparation tank, and stirring and mixing; (3) starting a rotor pump and a homogenizing pump to form internal circulation in the liquid preparation tank, opening a ball valve of a charging hopper, adding xanthan gum and pregelatinized starch, closing the valve of the hopper, and homogenizing and stirring until the step (6) is finished; (4) weighing cane sugar, adding the cane sugar into boiling water at 100 DEG C, and stirring for dissolving; 5) continuously stirring in the liquid preparation tank, adding a sucrose solution, washing the container with water, and adding into the liquid preparation tank; 6) adding anhydrous citric acid and sodium benzoate into the liquid preparation tank, and stirring for more than 1 hour after the steps 3-6 are finished; 7) closing the homogenizing pump, adding an ibuprofen dispersion liquid into the liquid preparation tank, washing the dispersion container with water for several times, and stirring; (8) adding essence into the liquid preparation tank, and stirring; 9) adding the total amount of purified water, and stirring; and 10) filling. The drops with good dispersibility and good stability are obtained by screening the prescription and optimizing the preparation process.

Provided are an anti-IL-5 antibody lyophilized formulation and a reconstituted formulation thereof. The anti-IL-5 antibody lyophilized formulation comprises an anti-IL-5 antibody, a histidine buffer, sucrose, and polysorbate 80. The anti-IL-5 antibody lyophilized formulation has excellent stability, has a lower osmotic pressure after reconstitution, reduces injection pain for patients, and is more suitable for clinical use.

The present invention is directed to methods for treating or preventing neuroinflammation in a subject by administering an effective amount of a single-domain antibody (sdAb) comprising SEQ ID NO:1. The method is applicable to subjects with multiple sclerosis, including secondary progressive, primary progressive, and relapsing-remitting forms. Administration may be intravenous, subcutaneous, or intrathecal, with dosage regimens including daily administration, loading and maintenance doses, or continuous infusion. The method may be initiated upon first clinical signs of central nervous system demyelination and continued for at least 14 days. The sdAb may be co-administered with a pharmaceutically acceptable excipient such as mannitol, sucrose, or polysorbate 80, and optionally combined with disease-modifying therapies including interferon-β, glatiramer acetate, fingolimod, or ocrelizumab. The invention provides a targeted approach for modulating neuroinflammatory processes in neurological disorders.

The invention belongs to the field of medicines, and particularly relates to a medicine composition containing vidicetumab as well as a preparation method and application of the medicine composition. The composition comprises the following components: vidicetumab, carilizumab, trehalose, L-, beta-glucopyranoside, beta-glucopyranoside and beta-glucopyranoside. The freeze-dried powder prepared from the ornithine, the histidine buffer system and the polysorbate 80 is high in stability, fast in redissolution and low in protein aggregate content. The invention also provides application of the compound and tegafur gimeracil oteracil oteracil oteracil oteracil oteracil oteracil oteracil oteracil oteracil oteracil oteracil

This invention discloses a nine-vitamin cod liver oil, comprising 8-12 parts cod liver oil, 1-1.4 parts vitamin A, 0.02-0.04 parts vitamin D3, 0.8-1.2 parts vitamin B1, 0.7-0.8 parts vitamin B2, 0.4-0.6 parts vitamin B6, 27-33 parts vitamin C, 0.4-0.6 parts vitamin E, 0.2-0.4 parts nicotinamide, 0.4-0.6 parts calcium pantothenate, 70-80 parts polysorbate 80, 0.1-0.6 parts fat-soluble antioxidant, 0.5-4 parts fat-soluble preservative, 8-12 parts water-soluble preservative, 4-6 parts water-soluble antioxidant, 40-50 parts sodium bicarbonate, 22-30 parts citric acid, 44-60 parts sodium citrate, and 3200-4800 parts sucrose. This invention provides a nine-dimensional cod liver oil and its preparation method, which can not only maintain the clarity of the liquid, but also keep the content of indicator components stable.

The application relates to the technical field of biological pharmacy, and discloses a preparation method of a ready-to-use stable 3D-MLA adjuvant solution, which comprises the following steps: dissolving citric acid monohydrate and trisodium citrate dihydrate in water for injection to prepare a citrate buffer; under stirring, adding polysorbate 80 into the citrate buffer to dissolve the polysorbate 80; under stirring, adding 3D-MLA into the obtained solution to dissolve the 3D-MLA; adjusting the pH value of the solution; using water for injection to fix the volume; performing sterilization filtration through a filter membrane, filling the filtrate into a container and sealing the container; and cold storage. Through the citrate buffer and the adjustment of the pH value of the adjuvant solution, the combination of the buffer system and the pH environment effectively inhibits the chemical degradation of the 3D-MLA in the water for injection, the technical problem that the solution is prone to degradation is solved, and a ready-to-use preparation which can be stably stored under cold storage conditions is obtained.

This invention relates to the field of veterinary drug formulation and new feed additive technology, and proposes a compound emulsion based on hydroxypropyl chitosan-encapsulated essential oil-phytosterols, its preparation method, and its application. The compound emulsion is composed of the following raw materials in weight percentages: 10%–15% hydroxypropyl chitosan essential oil-encapsulated emulsion, 6%–9% phytosterol liposome dispersion, 6%–10% medium-chain triglycerides, 1.5%–2.5% beeswax, 2%–3% hydrogenated soybean lecithin, 3%–4% polysorbate 80, 0.3%–0.5% xanthan gum, 5%–7% glycerol, 3%–5% glucose, 0.05%–0.1% potassium sorbate, 0.005%–0.008% antioxidant, and the balance being water. This technical solution solves the problem of poor treatment efficacy for bacterial diseases in calves in related technologies.